Palatin Technologies (NYSEAMERICAN:PTN) Share Price Passes Above Two Hundred Day Moving Average of $0.00

Palatin Technologies, Inc. (NYSEAMERICAN:PTNGet Free Report)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $1.83. Palatin Technologies shares last traded at $1.79, with a volume of 82,522 shares.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Palatin Technologies in a research note on Thursday, June 20th.

View Our Latest Stock Report on Palatin Technologies

Palatin Technologies Stock Up 1.4 %

The firm has a market cap of $28.81 million, a price-to-earnings ratio of -0.72 and a beta of 1.00.

Palatin Technologies (NYSEAMERICAN:PTNGet Free Report) last announced its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.03). During the same period last year, the business earned ($0.63) earnings per share. On average, equities research analysts predict that Palatin Technologies, Inc. will post -2.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Palatin Technologies stock. Armistice Capital LLC acquired a new position in Palatin Technologies, Inc. (NYSEAMERICAN:PTNFree Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 590,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,348,000. Armistice Capital LLC owned about 4.29% of Palatin Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.50% of the company’s stock.

Palatin Technologies Company Profile

(Get Free Report)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

Featured Stories

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.